New hope for lung cancer: drug combo targets resistant tumors
NCT ID NCT05616624
First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This study is for people with small cell or non-small cell lung cancer whose cancer has worsened after initial treatment. It tests a combination of three drugs: ADI-PEG 20, gemcitabine, and docetaxel. The first part finds the safest dose, and the second part checks how well the combination works at shrinking tumors or stopping growth. About 31 participants are expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.